Radiotherapy access in Belgium: How far are we from evidence-based utilisation?
INTRODUCTION
Underutilisation of radiotherapy has been observed worldwide. To evaluate the current situation in Belgium, optimal utilisation proportions (OUPs) adopted from the European SocieTy for Radiotherapy and Oncology - Health Economics in Radiation Oncology (ESTRO-HERO) project were compared to actual utilisation proportions (AUPs) and with radiotherapy advised during the multidisciplinary cancer team (MDT) meetings. In addition, the impact of independent variables was analysed.


MATERIALS AND METHODS
AUPs and advised radiotherapy were calculated overall and by cancer type for 110,810 unique cancer diagnoses in 2009-2010. Radiotherapy utilisation was derived from reimbursement data and distinguished between palliative and curative intent external beam radiotherapy (EBRT) and/or brachytherapy (BT). Sensitivity analyses regarding the influence of the follow-up period, the survival length and patient's age were performed. Advised radiotherapy was calculated based on broad treatment categories as reported at MDT meetings.


RESULTS
The overall AUP of 37% (39% including BT) was lower than the OUP of 53%, but in line with advised radiotherapy (35%). Large variations by tumour type were observed: in some tumours (e.g. lung and prostate cancer) AUP was considerably lower than OUP, whereas in others there was reasonable concordance (e.g. breast and rectal cancer). Overall, 84% of treatments started within 9 months following diagnosis. Survival time influenced AUP in a cancer type-dependent way. Elderly patients received less radiotherapy.


CONCLUSION
Although the actually delivered radiotherapy in Belgium aligns well to MDT advices, it is lower than the evidence-based optimum. Further analysis of potential barriers is needed for radiotherapy forecasting and planning, and in order to promote adequate access to radiotherapy.
['Lievens|Y|Y|', 'De Schutter|H|H|', 'Stellamans|K|K|', 'Rosskamp|M|M|', 'Van Eycken|L|L|', '|||']
D000067575:Administrative Claims, Healthcare D000367:Age Factors D000368:Aged D000369:Aged, 80 and over D001530:Belgium D001918:Brachytherapy D000066491:Clinical Decision-Making D016208:Databases, Factual D019317:Evidence-Based Medicine D005260:Female D019983:Guideline Adherence D017048:Health Care Costs D006297:Health Services Accessibility D006300:Health Services Misuse D006801:Humans D007349:Insurance, Health, Reimbursement D008297:Male D008875:Middle Aged D009369:Neoplasms D010166:Palliative Care D010348:Patient Care Team D018579:Patient Selection D017410:Practice Guidelines as Topic D010818:Practice Patterns, Physicians' D017064:Process Assessment, Health Care D016019:Survival Analysis D013997:Time Factors D016896:Treatment Outcome
Access Utilisation Reimbursement External beam radiotherapy Brachytherapy Cancer incidence Multidisciplinary cancer team meetings